Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topical antifungal agents.

J M Ernest1

  • 1Department of Obstetrics and Gynecology, Wake Forest University Medical Center, Winston-Salem, North Carolina.

Obstetrics and Gynecology Clinics of North America
|September 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spontaneous resolution of asymptomatic Chlamydia trachomatis in pregnancy.

Obstetrics and gynecology·2005
Same author

Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women.

Obstetrics and gynecology·2003
Same author

Early pregnancy threshold vaginal pH and Gram stain scores predictive of subsequent preterm birth in asymptomatic women.

American journal of obstetrics and gynecology·2003
Same author

Sexual intercourse association with asymptomatic bacterial vaginosis and Trichomonas vaginalis treatment in relationship to preterm birth.

American journal of obstetrics and gynecology·2002
Same author

Antibiotics and preterm labor.

Current women's health reports·2002
Same author

Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection.

The New England journal of medicine·2001
Same journal

Bridging Science and Practice in Gender-Affirming Care: A Compendium for Gynecologists.

Obstetrics and gynecology clinics of North America·2026
Same journal

Evidence, Clinical Expertise, and Research Gaps in Gender-Affirming Care.

Obstetrics and gynecology clinics of North America·2026
Same journal

Evaluation and Management of the Pediatric Gender-Diverse Patient.

Obstetrics and gynecology clinics of North America·2026
Same journal

Expanding Access to Cervical Cancer Screening for Transgender and Nonbinary Individuals.

Obstetrics and gynecology clinics of North America·2026
Same journal

Updates on Breast Cancer Screening and Special Considerations for Transgender Men and Women.

Obstetrics and gynecology clinics of North America·2026
Same journal

Contraceptive Needs of the Transmasculine Patient.

Obstetrics and gynecology clinics of North America·2026
See all related articles

Topical azole antifungals are preferred for vulvovaginal candidiasis over older agents like nystatin. Treatment duration and agent choice depend on individual patient factors, with no proven harm to pregnancy.

Area of Science:

  • Mycology
  • Pharmacology
  • Obstetrics and Gynecology

Background:

  • Limited understanding of fungal cell architecture and antifungal mechanisms hinders topical agent development.
  • Nystatin, an older antifungal, has been largely replaced by imidazoles and triazoles for vulvovaginal candidiasis.
  • Current treatment guidelines for vulvovaginal candidiasis lack a clear superior azole agent or dosing regimen.

Purpose of the Study:

  • To review current knowledge on topical antifungal agents for vulvovaginal candidiasis.
  • To discuss factors influencing the choice of antifungal agent and treatment duration.
  • To address safety considerations during pregnancy and the issue of antifungal resistance.

Main Methods:

  • Literature review of current antifungal agents and treatment strategies for vulvovaginal candidiasis.

Related Experiment Videos

  • Analysis of factors influencing agent selection, including patient preference and clinical presentation.
  • Evaluation of safety data regarding topical azole use during pregnancy and the potential for resistance.

    • Main Results:

    • Topical azoles are now the preferred treatment for vulvovaginal candidiasis, surpassing nystatin.
    • Short-term therapy (1-3 days) is recommended for uncomplicated cases, with longer durations (6-14 days) for recurrent cases or during pregnancy.
    • Patient factors like hypersensitivity, cost, and vehicle preference guide agent selection.
    • Topical azoles have not demonstrated harm to fetuses or pregnancies.
    • Antifungal resistance is not a significant concern for occasional or chronic candidal vaginitis.

    Conclusions:

    • Treatment choice for vulvovaginal candidiasis should be individualized based on clinical factors and patient preferences.
    • Topical azoles are safe and effective for treating vulvovaginal candidiasis, including during pregnancy.
    • Antifungal resistance is rarely a cause of treatment failure in candidal vaginitis.